<!DOCTYPE html PUBLIC >
<html>

  <head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <link rel="stylesheet" type="text/css" href="livesite_css\defaults.css">
    <link rel="stylesheet" type="text/css" href="livesite_css\projectroot.css">
    <link rel="stylesheet" type="text/css" href="livesite_css\style.css">
    <title>
      Assess Risk
    </title>
    <script src="js\jquery.js"></script>
    <script src="js\jquery_ui\jquery-ui.js"></script>
    <script src="js\mCustomScrollbar\jquery.mCustomScrollbar.js"></script>
    <script src="js\menu.js"></script>
    <script src="js\custom-accordion.js"></script>
	<script src="js\jquery.cookie.js"></script>
	<script src="js\text-resize.js"></script>
	<script src="js\jquery.colorbox.js"></script>
	<script src="js\colorbox-script.js"></script>
  </head>

  <body>
    <div class="page" id="page">
      <div class="page-width">
        <div id="header">
          <div class="header clearfix">
            <div class="hd-wr clearfix">
              <div class="fl logo">

                <a href="index.html">

                  <img alt="Project Root Logo" height="63" src="img/logo.png" width="332">
                </a>

              </div>
              <div class="fr">
                <div class="search">
                  &nbsp;
                </div>
 
                              <div class="txt-rsg fr">
                                <a class="small " href="javascript:void(0);">
                                  A
                                </a>

                                <a class="med active" href="javascript:void(0);">
                                  A
                                </a>

                                <a class="large" href="javascript:void(0);">
                                  A
                                </a>
                              </div>
                          </div>
                      </div>
                  </div>
                  <div id="navigation" class="horizontal">
                    <div id="block-system-main-menu" class="block block-system block-menu menu-dropdown block-none clearfix">
                      <div class="inner tb-terminal">
                        <div class="top">
                          <div class="top-inset-1 tb-terminal">
                            <div class="top-inset-2 tb-terminal">
                            </div>
                          </div>
                        </div>
                        <div class="middle tb-terminal">
                          <div class="content">
                            <ul class="menu pulldown-processed menu-dropdown-js-enabled pulldown">
                              <li class="first leaf level-1 menu-link-2316">
                                <a href="index.html" title="">
                                  Home
                                </a>
                              </li>
                              <li class="expanded level-1 menu-link-2971">
                                <a title="" class="menu-dropdown-with-ul">
                                  About Rethink Opioids
                                  <span class="more-indicator">
                                    »
                                  </span>
                                </a>

                                <ul class="menu" style="visibility: hidden; display: none;">
                                  <li class="first leaf level-2 menu-link-2326">
                                    <a href="what-is-project-root.html" title="">
                                      What Is Rethink Opioids?
                                    </a>
                                  </li>
                                  <li class="last leaf level-2 menu-link-2331">
                                    <a href="steering-committee.html">
                                      Meet the Steering Committee
                                    </a>
                                  </li>
                                </ul>
                              </li>
                              <li class="expanded level-1 menu-link-2976">
                                <a title="" class="menu-dropdown-with-ul">
                                  Why Rethink Opioids?
                                  <span class="more-indicator">
                                    »
                                  </span>
                                </a>

                                <ul class="menu" style="visibility: hidden; display: none;">
                                  <li class="first collapsed level-2 menu-link-2336">
                                    <a href="why-rethink-opioids.html">
                                      Why We Must Rethink Opioids
                                    </a>
                                  </li>
                                  <li class="leaf level-2 menu-link-2341">
                                    <a href="prescription-opioid-abuse.html">
                                      The Problem of Prescription Opioid Abuse
                                    </a>
                                  </li>
                                  <li class="last leaf level-2 menu-link-2346">
                                    <a href="concerns-of-health-care-professionals.html">
                                      Concerns of Health Care Professionals and Patients
                                    </a>
                                  </li>
                                </ul>
                              </li>
                              <li class="expanded active-trail level-1 menu-link-2981">
                                <a title="" class="menu-dropdown-with-ul">
                                  Practical Approaches
                                  <span class="more-indicator">
                                    »
                                  </span>
                                </a>

                                <ul class="menu" style="display: none; visibility: hidden;">
                                  <li class="first leaf level-2 menu-link-2351">
                                    <a href="practical-approaches.html">
                                      A Framework for Prescribing
                                    </a>
                                  </li>
                                  <li class="collapsed level-2 menu-link-2356">
                                    <a href="appropriate-treatment">
                                      Clinically Appropriate Treatment Selection
                                    </a>
                                  </li>
                                  <li class="collapsed level-2 active-trail menu-link-2371">
                                    <a href="applying-universal-precautions.html"  class="active-trail active">
                                      Applying Universal Precautions When Prescribing
                                    </a>
                                  </li>
                                  <li class="last collapsed level-2 menu-link-2396">
                                    <a href="principles-in-practice.html">
                                      Universal Precautions in Practice: Case Studies
                                    </a>
                                  </li>
                                </ul>
                              </li>
                              <li class="last expanded level-1 menu-link-2986">
                                <a title="" class="menu-dropdown-with-ul">
                                  Tools and Resources
                                  <span class="more-indicator">
                                    »
                                  </span>
                                </a>

                                <ul class="menu" style="display: none; visibility: hidden;">
                                  <li class="first leaf level-2 menu-link-2421">
                                    <a href="tools-and-resources.html">
                                      Overview of Resources
                                    </a>
                                  </li>
                                  <li class="leaf level-2 menu-link-2426">
                                    <a href="patient-assessment-tools.html">
                                      Patient Assessment Tools
                                    </a>
                                  </li>
                                  <li class="leaf level-2 menu-link-2431">
                                    <a href="precautions-implementation-tool.html">
                                      Universal Precautions Implementation Tool
                                    </a>
                                  </li>
                                  <li class="leaf level-2 menu-link-2436">
                                    <a href="guidelines.html">
                                      Guidelines and Templates
                                    </a>
                                  </li>
                                  <li class="last leaf level-2 menu-link-2441">
                                    <a href="glossary.html">
                                      Glossary
                                    </a>
                                  </li>
                                </ul>
                              </li>
                            </ul>
                          </div>
                        </div>
                        <div class="bottom">
                          <div class="bottom-inset-1 tb-terminal">
                            <div class="bottom-inset-2 tb-terminal">
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
              </div>
              <div id="content">
                <div id="sidebar-a" class="col-a sidebar left">
                  <div class="block">
                    <ul class="menu">
                      <li class="first leaf level-1 menu-link-3076">
                        <a href="applying-universal-precautions.html" title="">
                          Applying Universal Precautions When Prescribing
                        </a>
                      </li>
                      <li class="leaf active-trail level-1 menu-link-3081">
                        <a href="assess-risk.html" title="" class="active-trail active">
                          Step 1: Assess Risk
                        </a>
                      </li>
                      <li class="leaf level-1 menu-link-3086">
                        <a href="select-agent.html" title="">
                          Step 2: Select Agent
                        </a>
                      </li>
                      <li class="leaf level-1 menu-link-3091">
                        <a href="dialogue-with-patient.html" title="">
                          Step 3: Dialogue With Patient
                        </a>
                      </li>
                      <li class="last leaf level-1 menu-link-3096">
                        <a href="monitor-treatment.html" title="">
                          Step 4: Monitor Treatment
                        </a>
                      </li>
                    </ul>
                  </div>
                  <div>
                    <div class="left-panel flw">
                      <img src="img/left-hand-art4.png">
                    </div>
                  </div>
                </div>
                <div id="main" class="col-c">
                  <div id="custom-accordion">
                    <h3 class="assess_risk_tab1">
                      Step 1: Assess Risk
                    </h3>
                    <div>
                      <div class="acc_wrapper clearfix">
                        <div class="acc_cont clearfix">
                          <div class="acc_text">
                            <h1>
                              Universal Precautions, Step 1: Assess Risk
                            </h1>
                            <p>
                              After deciding that opioid therapy may be
                              <em>
                                clinically
                              </em>
                              appropriate for a patient with chronic pain, it is important to assess the patient for existing substance abuse, addiction potential, and the overall risk for aberrant behavior relating to opioid use before providing the prescription.<sup><a class="accordin-scroll" href="#1_ref_1">1</a>-<a class="accordin-scroll" href="#1_ref_7">7</a></sup>
                              Aberrant behavior is any patient behavior that suggests the presence of substance abuse or addiction.<sup><a class="accordin-scroll" href="#1_ref_8">8</a>,<a class="accordin-scroll" href="#1_ref_9">9</a></sup>
                              These behaviors may indicate misuse, abuse, or diversion of the medication and may range from unauthorized dose-escalation and hoarding of medication to frequent &ldquo;losing&rdquo; of medication, &ldquo;doctor shopping,&rdquo; tampering with or manipulation of the medication, forging prescriptions, and selling prescriptions.<sup><a class="accordin-scroll" href="#1_ref_2">2</a>,<a class="accordin-scroll" href="#1_ref_3">3</a>,<a class="accordin-scroll" href="#1_ref_10">10</a>,<a class="accordin-scroll" href="#1_ref_11">11</a></sup>
                              Note, however, that the definitions of what constitutes aberrant behavior have not been consistent in the literature.<sup><a class="accordin-scroll" href="#1_ref_1">1</a>,<a class="accordin-scroll" href="#1_ref_12">12</a></sup>
                            </p>
                            <p>
                              Numerous tools are available to help assess opioid risk and, importantly, to help document that you have done so.<sup><a class="accordin-scroll" href="#1_ref_6">6</a></sup>
                              Note that risk-assessment tools not discussed here also may merit consideration.
                            </p>
                            <p>
                              The components of risk assessment that are presented here are intended to be used together to help determine the appropriateness of opioid therapy for patients with chronic pain. However, none of these approaches, alone or together, can provide definitive assessment of an individual patient&rsquo;s risk.<sup><a class="accordin-scroll" href="#1_ref_13">13</a></sup>
                              Ultimately, every patient is potentially at risk for aberrant behavior related to opioids. Universal precautions, applied throughout the course of patient management, are intended to help mitigate that risk.<sup><a class="accordin-scroll" href="#1_ref_5">5</a>,<a class="accordin-scroll" href="#1_ref_7">7</a></sup>
                            </p>
                            <p>
                              It is important to explain to patients that the risk-assessment process is a fundamental part of applying universal precautions for opioid therapy, and that the process is intended to help ensure they receive the best care possible.<sup><a class="accordin-scroll" href="#1_ref_6">6</a></sup>
                              For more suggestions on how to discuss aspects of the 4-step approach to applying universal precautions in patients receiving or being considered for opioid therapy, refer to the
                              <a href="precautions-implementation-tool.html" id="precautions_implementation_tool_Step1">
                                Universal Precautions Implementation Tool
                              </a>
                              .
                            </p>
                            <div class="note">
                              <p>
                                Select a tab below to learn more about suggested ways to assess prescription opioid risk in patients with chronic pain.
                              </p>
                            </div>
                            <div class="next">
                              <div class="next_2 fl n-width2">
                                Step 2:
                                <a href="select-agent.html" id="select-agent1">
                                  Select Agent
                                </a>
                              </div>
                            </div>
                          </div>
                          <div class="references"><p>References</p><ol><li><a name="one" id="1_ref_1"></a>Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society&ndash;American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. <em>J Pain</em>. 2009;10(2):113-130. PMID:<a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19187889" class="ext-link">19187889</a><span class="ext"></span></li><li><a name="two" id="1_ref_2"></a>US Department of Veterans Affairs, US Department of Defense. <em>VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain</em>. Version 2.0. Washington, DC: US Dept of Veterans Affairs, US Dept of Defense; 2010. <a href="http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf" class="ext-link" target="_blank">http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="three" id="1_ref_3"></a>Washington State Agency Medical Directors’ Group (AMDG). <em>Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An Educational Aid to Improve Care and Safety With Opioid Therapy</em>. 2010 Update. Olympia, WA: Washington State Agency Medical Directors Group; 2010. <a href="http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf" class="ext-link" target="_blank">http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="four" id="1_ref_4"></a>Utah Department of Health. <em>Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain</em>. Salt Lake City, UT: Utah Dept of Health; 2009. <a href="http://www.dopl.utah.gov/licensing/forms/OpioidGuidlines.pdf" class="ext-link" target="_blank">http://www.dopl.utah.gov/licensing/forms/OpioidGuidlines.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="five" id="1_ref_5"></a>Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. <em>J Pain</em>. 2010;11(7):602-611. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20444651" class="ext-link">20444651</a><span class="ext"></span></li><li><a name="six" id="1_ref_6"></a>Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. <em>Pain Med</em>. 2005;6(2):107-112. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15773874" class="ext-link">15773874</a><span class="ext"></span></li><li><a name="seven" id="1_ref_7"></a>Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. <em>Mayo Clin Proc</em>. 2009;84(7):593-601. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19567713" class="ext-link">19567713</a><span class="ext"></span></li><li><a name="eight" id="1_ref_8"></a>O’Connor AB, Turk DC, Dworkin RH, et al. Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. <em>Pain</em>. 2013;154(11):2324-2334.</li><li><a name="nine" id="1_ref_9"></a>Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. <em>Clin J Pain</em>. 2010;26(9):770-776. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20842012" class="ext-link">20842012</a><span class="ext"></span></li><li><a name="ten" id="1_ref_10"></a>Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain [review]. <em>J Opioid Manag</em>. 2011;7(3):235-245. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21823554" class="ext-link">21823554</a><span class="ext"></span></li><li><a name="eleven" id="1_ref_11"></a>Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. <em>Clin J Pain</em>. 2007;23(8):648-660. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17885342" class="ext-link">17885342</a><span class="ext"></span></li><li><a name="twelve" id="1_ref_12"></a>Sullivan M. Clarifying opioid misuse and abuse [editorial]. <em>Pain</em>. 2013;154(11):2239-2240.</li><li><a name="thirteen" id="1_ref_13"></a>Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. <em>Pain Physician</em>. 2012;15(3 suppl):ES67-ES92. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22786463" class="ext-link">22786463</a><span class="ext"></span></li></ol></div>
                        </div>
                      </div>
                    </div>
                    <h3 class="risk_tool_tab2">
                      Opioid Risk Tool
                    </h3>
                    <div>
                      <div class="acc_wrapper clearfix">
                        <div class="acc_cont clearfix">
                          <div class="acc_text">
                            <h1>
                              Universal Precautions, Step 1: Assess Risk
                            </h1>
                            <h3>
                              The Opioid Risk Tool May Help With Opioid Risk Assessment
                            </h3>
                            <div class="acc_img fl">
                              <a href="pdfs/Opioid-Risk-Tool.pdf" target="_blank">
                                <img alt="Opoid Risk Tool" src="img/3.2.1.1-Opioid-Risk-Tool_1.png" />
                              </a>
                              <div class="linklabel">
                                Click on image above to view and download ORT
                              </div>
                              <div class="imgreftext">
                                Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.
                                <em>
                                  Pain Med
                                </em>
                                . 2005;6(6):432-442. Used with permission.
                              </div>
                            </div>
                            <p>
                              The Opioid Risk Tool (ORT) consists of 5 items that may help assess a patient&rsquo;s risk for
                              <em>
                                aberrant behavior
                              </em>
                              before prescribing an opioid (see
                              <a href="glossary" id="agent_glossary">
                                Glossary
                              </a>
                              ).
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_1">
                                  1
                                </a>
                              </sup>
                              This tool considers the patient&rsquo;s family and personal history of substance abuse (alcohol, illegal or prescription drugs), patient age and sex, any history of preadolescent sexual abuse, and the presence of
                              <a href="javascript:void(0);" id="assess_risk_step3">
                                psychological illness
                              </a>
                              .
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_1">
                                  1
                                </a>
                              </sup>
                              The ORT can be completed by the patient or administered by you.
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_2">
                                  2
                                </a>
                              </sup>
                            </p>
                            <p>
                              Each risk factor that is present is assigned a number value. These numbers are totaled, providing a sum that suggests whether the patient is at low (score of 0-3), moderate (score of 4-7), or high (score &ge;8) risk for aberrant behavior.
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_1">
                                  1
                                </a>
                              </sup>
                              Of course, these are subjective descriptions of risk, and it is a matter of your discretion how patient management may be influenced by the results of the ORT.
                            </p>
                            <p>
                              In a preliminary study of 185 patients treated at a single pain clinic, the ORT demonstrated a high degree of sensitivity and specificity for assessing patients&rsquo; risk for aberrant behavior relating to prescription opioids.
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_1">
                                  1
                                </a>
                              </sup>
                              However, a more recent single-center study of 125 patients found that the ORT was
                              <em>
                                not
                              </em>
                              strongly predictive of moderate to severe aberrant drug-related behavior.
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_3">
                                  3
                                </a>
                              </sup>
                              Use of the ORT is currently included in several
                              <a href="guidelines" id="assess_guidelines">
                                treatment guidelines
                              </a>
                              for the management of patients receiving long-term opioid therapy.
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_4">
                                  4
                                </a>
                                -
                                <a class="accordin-scroll" href="#2_ref_6">
                                  6
                                </a>
                              </sup>
                              The ORT may be best utilized in conjunction with other risk-assessment approaches, to create the most complete picture possible of a patient&rsquo;s potential risk.
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_7">
                                  7
                                </a>
                              </sup>
                            </p>
                            <p>
                              Depending on the results of your risk assessment of the patient (based on the ORT and/or other measures), you may decide to initiate opioid therapy or you may wish to consult with or refer to an appropriate specialist (such as a pain medicine or addiction specialist).
                              <sup>
                                <a class="accordin-scroll" href="#2_ref_5">
                                  5
                                </a>
                                ,
                                <a class="accordin-scroll" href="#2_ref_8">
                                  8
                                </a>
                              </sup>
                            </p>
                            <div class="next">
                              <div class="next_2 fl n-width2">
                                Step 2:
                                <a href="select-agent" id="select_agent2">
                                  Select Agent
                                </a>
                              </div>
                            </div>
                          </div>
                          <div class="references"><p>References</p><ol><li><a name="ort_one" id="2_ref_1"></a>Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. <em>Pain Med</em>. 2005;6(6):432-442. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16336480" class="ext-link">16336480</a><span class="ext"></span></li><li><a name="ort_two" id="2_ref_2"></a>Jones T, Passik SD. A comparison of methods of administering the opioid risk tool. <em>J Opioid Manag</em>. 2011;7(5):347-351. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22165033" class="ext-link">22165033</a><span class="ext"></span></li><li><a name="ort_three" id="2_ref_3"></a>Witkin LR, Diskina D, Fernandes S, Farrar JT, Ashburn MA. Usefulness of the opioid risk tool to predict aberrant drug-related behavior in patients receiving opioids for the treatment of chronic pain. <em>J Opioid Manag</em>. 2013;9(3):177-187. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23771568" class="ext-link">23771568</a><span class="ext"></span></li><li><a name="ort_four" id="2_ref_4"></a>Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society&ndash;American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. <em>J Pain</em>. 2009;10(2):113-130. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19187889" class="ext-link">19187889</a><span class="ext"></span></li><li><a name="ort_five" id="2_ref_5"></a>US Department of Veterans Affairs, US Department of Defense. <em>VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain</em>. Version 2.0. Washington, DC: US Dept of Veterans Affairs, US Dept of Defense; 2010. <a href="http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf" class="ext-link" target="_blank">http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="ort_six" id="2_ref_6"></a>Washington State Agency Medical Directors’ Group (AMDG). <em>Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An Educational Aid to Improve Care and Safety With Opioid Therapy</em>. 2010 Update. Olympia, WA: Washington State Agency Medical Directors Group; 2010. <a href="http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf" class="ext-link" target="_blank">http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="ort_seven" id="2_ref_7"></a>Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. <em>Pain Physician</em>. 2012;15(3 suppl):ES67-ES92. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22786463" class="ext-link">22786463</a><span class="ext"></span></li><li><a name="ort_eight" id="2_ref_8"></a>Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. <em>Pain Med</em>. 2005;6(2):107-112. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15773874" class="ext-link">15773874</a><span class="ext"></span></li></ol></div>
                        </div>
                      </div>
                    </div>
                    <h3 class="psychological_assessment_tab3">
                      Psychological Assessment
                    </h3>
                    <div>
                      <div class="acc_wrapper clearfix">
                        <div class="acc_cont clearfix">
                          <div class="acc_text">
                            <h1>
                              Universal Precautions, Step 1: Assess Risk
                            </h1>
                            <h3>
                              The Patient Health Questionnaire 4 (PHQ-4) May Help With Psychological Assessment
                            </h3>
                            <div class="acc_img fl">
                              <a class="phq_img" href="pdfs/PHQ-4.pdf" target="_blank">
                                <img alt="PHQ-4" src="img/3.2.1.2-PHQ_4_1.png" />
                              </a>
                              <div class="linklabel">
                                Click on image above to view and download PHQ-4
                              </div>
                              <div class="imgreftext">
                                Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4.
                                <em>
                                  Psychosomatics
                                </em>
                                . 2009;50(6):613-621.
                              </div>
                            </div>
                            <p>
                              Specific psychological illnesses may contribute to opioid risk, including attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, bipolar disorder, and depression.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_1">
                                  1
                                </a>
                              </sup>
                              Opioid therapy may need to be reconsidered in a patient with moderate to severe psychological illness.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_2">
                                  2
                                </a>
                              </sup>
                              Referral to a pain or mental health specialist may be considered in such cases.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_3">
                                  3
                                </a>
                              </sup>
                            </p>
                            <p class="patient_link">
                              The brief
                              <a href="img/PHQ-4.pdf" target="_blank">
                                Patient Health Questionnaire 4 (PHQ-4)
                              </a>
                              may help screen for the presence of depression (and anxiety) in patients being considered for opioid therapy.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_4">
                                  4
                                </a>
                                ,
                                <a class="accordin-scroll" href="#3_ref_5">
                                  5
                                </a>
                              </sup>
                            </p>
                            <p>
                              The 4-item PHQ-4 asks patients to indicate how often they have been bothered by 4 specific problems (2 suggesting anxiety, 2 suggesting depression) during the past 2 weeks.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_4">
                                  4
                                </a>
                                ,
                                <a class="accordin-scroll" href="#3_ref_5">
                                  5
                                </a>
                              </sup>
                              The response to each question yields a score from 0 (not bothered at all) to 3 (bothered nearly every day).
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_6">
                                  6
                                </a>
                              </sup>
                            </p>
                            <p>
                              A total score of 3 or higher on the 2 depression questions has been shown to have a sensitivity of 83% and a specificity of 90% for major depressive disorder.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_7">
                                  7
                                </a>
                              </sup>
                              A total score of 3 or higher on the 2 anxiety questions has been shown to have a sensitivity of 86% (95% CI, 76%-93%) and a specificity of 83% (95% CI, 80%-85%) for generalized anxiety disorder.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_8">
                                  8
                                </a>
                              </sup>
                            </p>
                            <p>
                              The validity of the PHQ-4 has been examined in multiple studies in the general population,
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_4">
                                  4
                                </a>
                                ,
                                <a class="accordin-scroll" href="#3_ref_5">
                                  5
                                </a>
                              </sup>
                              It should be emphasized, however, that this screening tool should not be used independently to definitively diagnose depression or anxiety, and is an adjunct to your clinical assessment.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_4">
                                  4
                                </a>
                              </sup>
                            </p>
                            <div class="next">
                              <div class="next_2 fl n-width2">
                                Step 2:
                                <a href="select-agent" id="select_agent3">
                                  Select Agent
                                </a>
                              </div>
                            </div>
                          </div>
                         <div class="references"><p>References</p><ol><li><a name="pa_one" id="3_ref_1"></a>Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. <em>Pain Med</em>. 2005;6(6):432-442. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16336480" class="ext-link">16336480</a><span class="ext"></span></li><li><a name="pa_two" id="3_ref_2"></a>US Department of Veterans Affairs, US Department of Defense. <em>VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain</em>. Version 2.0. Washington, DC: US Dept of Veterans Affairs, US Dept of Defense; 2010. <a href="http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf" class="ext-link" target="_blank">http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="pa_three" id="3_ref_3"></a>Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. <em>Pain Med</em>. 2005;6(2):107-112. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15773874" class="ext-link">15773874</a><span class="ext"></span></li><li><a name="pa_four" id="3_ref_4"></a>Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. <em>Psychosomatics</em>. 2009;50(6):613-621. Used with permission. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19996233" class="ext-link">19996233</a><span class="ext"></span></li><li><a name="pa_five" id="3_ref_5"></a>Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire 4 (PHQ-4) in the general population. <em>J Affect Disord</em>. 2010;122(1-2):86-95. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19616305" class="ext-link">19616305</a><span class="ext"></span></li><li><a name="pa_six" id="3_ref_6"></a>Patient Health Question (PHQ) Screeners Web site. Instruction Manual: Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures. <a href="http://www.phqscreeners.com/instructions/instructions.pdf" class="ext-link" target="_blank">http://www.phqscreeners.com/instructions/instructions.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="pa_seven" id="3_ref_7"></a>Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire&ndash;2: validity of a two-item depression screener. <em>Med Care</em>. 2003;41(11):1284-1292. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kroenke+K%2C+Spitzer+RL%2C+Williams+JB%3A+The+Patient+Health+Questionnaire&ndash;2%3A+validity+of+a+two-item+depression+screener.+Med+Care+2003%3B+41%3A1284&ndash;1292." class="ext-link">14583691</a><span class="ext"></span></li><li><a name="pa_eight" id="3_ref_8"></a>Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. <em>Ann Intern Med</em>. 2007;146(5):317-325. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kroenke+K%2C+Spitzer+RL%2C+Williams+JBW%2C+et+al%3A+Anxiety+disorders+in+primary+care%3A+prevalence%2C+impairment%2C+comorbidity%2C+and+detection.+Ann+Intern+Med+2007%3B+146%3A317&ndash;325." class="ext-link">17339617</a><span class="ext"></span></li></ol></div>
                        </div>
                      </div>
                    </div>
                    <h3 class="monitoring_tab4">
                      Prescription Monitoring Program
                    </h3>
                    <div>
                      <div class="acc_wrapper clearfix">
                        <div class="acc_cont clearfix">
                          <h1>
                            Universal Precautions, Step 1: Assess Risk
                          </h1>
                          <div class="acc_img fl">
                            <img alt="" src="img/3.2.1.3_PMP%20map_v6.jpg" />
                            <div>
                              <p class="img-desc font11">
                                Adapted from Prescription Drug Monitoring Program Training and Technical Assistance Center Web site. http://www.pdmpassist.org/pdf/PDMPProgramStatus2014.pdf. Accessed May 20, 2014.
                              </p>
                              <div class="note">
                                <p>
                                  Note that this information may change over time and should be verified independently.
                                </p>
                              </div>
                            </div>
                          </div>
                          <div class="acc_text">
                            <p>
                              Forty-nine states and the territory of Guam either have a prescription monitoring program (PMP) in place or have passed legislation to implement one.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_1">
                                  1
                                </a>
                              </sup>
                              Also known as prescription drug monitoring programs (or PDMPs), these programs collect prescribing and dispensing data electronically submitted by pharmacies and practitioners, and monitor and analyze these data.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_2">
                                  2
                                </a>
                              </sup>
                              PMPs provide the data to legally authorized parties, including health care providers, regulatory boards, and law enforcement.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_2">
                                  2
                                </a>
                              </sup>
                            </p>
                            <p>
                              In some states, physicians are now required to check PMP data prior to prescribing a controlled substance, and other states are considering such legislation.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_3">
                                  3
                                </a>
                                ,
                                <a class="accordin-scroll" href="#4_ref_4">
                                  4
                                </a>
                              </sup>
                              You may wish to retrieve a patient&rsquo;s PMP records prior to the office visit, so you can have this information on hand during the visit.
                            </p>
                            <p>
                              Reviewing the PMP data may help detect &ldquo;doctor shopping&rdquo; or &ldquo;pharmacy shopping&rdquo;&mdash;the practice of deliberately obtaining controlled substances from multiple physicians or pharmacies.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_5">
                                  5
                                </a>
                                ,
                                <a class="accordin-scroll" href="#4_ref_6">
                                  6
                                </a>
                              </sup>
                              The information you obtain should be interpreted with caution since it may contain errors.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_5">
                                  5
                                </a>
                              </sup>
                              It also may indicate
                              <em>
                                unintentional
                              </em>
                              use of multiple controlled substances. However, any indication of a previously undisclosed history of controlled substance use should be discussed with the patient. Depending on the patient&rsquo;s response, consultation with or referral to a pain or addiction specialist may be advisable.
                              <sup>
                                <a class="accordin-scroll" href="#4_ref_5">
                                  5
                                </a>
                              </sup>
                            </p>
                            <p>
                              One source you may wish to access for state-by-state information about PMPs is the
                              <a href="http://www.pdmpassist.org" target="_blank">
                                Prescription Drug Monitoring Program Training and Technical Assistance Center
                              </a>
                              Web site.
                              <sup>
                                <a class="accordin-scroll" href="http://www.pdmpassist.org/pdf/PDMPProgramStatus2014.pdf">
                                  1
                                </a>
                              </sup>
                            </p>
                            <div class="note">
                              <p>
                                Note that potential PMP requirements are just one component of state and federal regulations. For more information about the PMP and other pertinent state and federal laws, check with your state&rsquo;s medical licensing board and the
                                <a href="http://www.justice.gov/dea/index.shtml">
                                  Drug Enforcement Administration
                                </a>
                                (DEA).You may wish to review a
                                <a href="http://www.cdc.gov/HomeandRecreationalSafety/Poisoning/laws/index.html">
                                  summary
                                </a>
                                of state prescription medication laws compiled by the Centers for Disease Control and Prevention.
                              </p>
                            </div>
                            <div class="next">
                              <div class="next_2 fl n-width2">
                                Step 2:
                                <a href="select-agent">
                                  Select Agent
                                </a>
                              </div>
                            </div>
                          </div>
                          <div class="references"><p>References</p><ol><li><a name="pmp_one" id="4_ref_1"></a>Prescription Drug Monitoring Program Training and Technical Assistance Center Web site. <a href="http://www.pdmpassist.org" class="ext-link" target="_blank">http://www.pdmpassist.org</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="pmp_two" id="4_ref_2"></a>US Dept of Justice, Drug Enforcement Administration Website. State Prescription Drug Monitoring Programs: Questions and Answers. Updated October 11, 2011. <a href="http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm" class="ext-link" target="_blank">http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm</a><span class="ext"></span>. Accessed October 8, 2014.</li><li><a name="pmp_three" id="4_ref_3"></a>National Conference of State Legislatures. Prevention of prescription drug overdose and abuse. Updated July 16, 2013. <a target="_blank" href="www.ncsl.org/issues-research/health/prevention-of-prescription-drug-overdose-and-abuse.aspx"> www.ncsl.org/issues-research/health/prevention-of-prescription-drug-overdose-and-abuse.aspx</a>. Accessed May 20, 2014.</li><li><a name="pmp_four" id="4_ref_4"></a>Prescription Monitoring Program (I-STOP). New York State Register: June 19, 2013. <a href="http://docs.dos.ny.gov/info/register/2013/june19/pdf/rulemaking.pdf" class="ext-link" target="_blank">http://docs.dos.ny.gov/info/register/2013/june19/pdf/rulemaking.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="pmp_five" id="4_ref_5"></a>Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. <em>J Pain</em>. 2010;11(7):602-611. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20444651" class="ext-link">20444651</a><span class="ext"></span></li><li><a name="pmp_six" id="4_ref_6"></a>McDonald DC, Carlson KE. Estimating the prevalence of opioid diversion by “doctor shoppers” in the United States. <em>PLoS One</em>. 2013;8(7):e69241. PMID:<a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23874923" class="ext-link">23874923</a><span class="ext"></span></li></ol></div>
                        </div>
                      </div>
                    </div>
                    <h3 class="last-tab drug_tab5">
                      Urine Drug Testing
                    </h3>
                    <div>
                      <div class="acc_wrapper clearfix">
                        <div class="acc_cont clearfix">
                          <h1>
                            Universal Precautions, Step 1: Assess Risk
                          </h1>
                          <div class="acc_img fl">
                            <img alt="" src="img/3.2.1.4_udt_algorithm_1.png" />
                          </div>
                          <div class="acc_text">
                            <p>
                              Baseline urine drug testing (UDT, or urine toxicology) is appropriate for every patient being considered for prescription opioid therapy for chronic pain.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_1">
                                  1
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                                -
                                <a class="accordin-scroll" href="#5_ref_9">
                                  9
                                </a>
                              </sup>
                              It can reveal the presence of illicit drugs, prescription opioid agents, and other prescription medications that can be abused.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_3">
                                  3
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                              </sup>
                            </p>
                            <p>
                              It is important to explain to patients that this baseline UDT is a universal precaution that is used with all patients.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                              </sup>
                              Patients who decline to provide a specimen for UDT may be considered unsuitable for chronic pain management with prescription opioids.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_10">
                                  10
                                </a>
                              </sup>
                              For suggestions on how to discuss UDT with patients (as well as other elements of universal precautions for opioid prescribing), see the
                              <a href="precautions-implementation-tool" id="assess_precaution">
                                Universal Precautions Implementation Tool
                              </a>
                              .
                            </p>
                            <p>
                              Point-of-care, immunoassay testing kits are available and can provide immediate results, although these tests tend to have high sensitivity but low specificity, and may miss some commonly used drugs.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_4">
                                  4
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_11">
                                  11
                                </a>
                              </sup>
                              Because of the potential for false negatives and false positives, these rapid results may need to be verified via laboratory testing (typically utilizing chromatography/mass spectrometry), which can be costly and time-consuming.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_4">
                                  4
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_12">
                                  12
                                </a>
                              </sup>
                              Depending on the results of point-of-care testing, you may wish to delay prescribing opioids until follow-up lab results are obtained or provide the patient with a limited quantity of medication.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                              </sup>
                            </p>
                            <p>
                              All UDT results&mdash;whether positive or negative&mdash;should be interpreted within the context of individual patient circumstances and the limitations of the testing methodology used.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_2">
                                  2
                                </a>
                                -
                                <a class="accordin-scroll" href="#5_ref_4">
                                  4
                                </a>
                              </sup>
                              When interpreting results of follow-up lab testing, it is important to discuss any unexpected results with the laboratory.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_3">
                                  3
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_5">
                                  5
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_10">
                                  10
                                </a>
                                ,
                                <a class="accordin-scroll" href="#5_ref_11">
                                  11
                                </a>
                              </sup>
                            </p>
                            <p>
                              When initial or follow-up test results contradict the patient&rsquo;s stated history, a discussion with the patient is an appropriate next step. If the discrepancies cannot be resolved to your satisfaction, you may wish to consult with or refer to a pain or addiction specialist.
                              <sup>
                                <a class="accordin-scroll" href="#5_ref_6">
                                  6
                                </a>
                              </sup>
                            </p>
                            <div class="next">
                              <div class="next_2 fl n-width2">
                                Step 2:
                                <a href="select-agent" id="select_agent4">
                                  Select Agent
                                </a>
                              </div>
                            </div>
                          </div>
                          <div class="references"><p>References</p><ol><li><a name="udt_one" id="5_ref_1"></a>Washington State Agency Medical Directors’ Group (AMDG). <em>Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An Educational Aid to Improve Care and Safety With Opioid Therapy</em>. 2010 Update. Olympia, WA: Washington State Agency Medical Directors Group; 2010. <a href="http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf" class="ext-link" target="_blank">http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="udt_two" id="5_ref_2"></a>Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society&ndash;American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. <em>J Pain</em>. 2009;10(2):113-130. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19187889" class="ext-link">19187889</a><span class="ext"></span></li><li><a name="udt_three" id="5_ref_3"></a>Heit HA, Gourlay DL. Urine drug testing in pain medicine. <em>J Pain Symptom Manage</em>. 2004;27(3):260-267. PMID:<a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15010104" class="ext-link">15010104</a><span class="ext"></span></li><li><a name="udt_four" id="5_ref_4"></a>Schonwald G. What is the role of urine drug testing (UDT) in the management of chronic non-cancer pain with opioids? <em>Pain Med</em>. 2012;13(7):853-856. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22804903" class="ext-link">22804903</a><span class="ext"></span></li><li><a name="udt_five" id="5_ref_5"></a>Peppin JF, Passik SD, Couto JE, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. <em>Pain Med</em>. 2012;13(7):886-896. PMID:<a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22694154" class="ext-link">22694154</a><span class="ext"></span></li><li><a name="udt_six" id="5_ref_6"></a>Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. <em>J Pain</em>. 2010;11(7):602-611. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20444651" class="ext-link">20444651</a><span class="ext"></span></li><li><a name="udt_seven" id="5_ref_7"></a>US Department of Veterans Affairs, US Department of Defense. <em>VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain</em>. Version 2.0. Washington, DC: US Dept of Veterans Affairs, US Dept of Defense; 2010. <a href="http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf" class="ext-link" target="_blank">http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="udt_eight" id="5_ref_8"></a>Utah Department of Health. <em>Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain</em>. Salt Lake City, UT: Utah Dept of Health; 2009. <a href="http://www.dopl.utah.gov/licensing/forms/OpioidGuidlines.pdf" class="ext-link" target="_blank">http://www.dopl.utah.gov/licensing/forms/OpioidGuidlines.pdf</a><span class="ext"></span>. Accessed May 20, 2014.</li><li><a name="udt_nine" id="5_ref_9"></a>Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. <em>Mayo Clin Proc</em>. 2009;84(7):593-601. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19567713" class="ext-link">19567713</a><span class="ext"></span></li><li><a name="udt_ten" id="5_ref_10"></a>Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. <em>Pain Med</em>. 2005;6(2):107-112. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15773874" class="ext-link">15773874</a><span class="ext"></span></li><li><a name="udt_eleven" id="5_ref_11"></a>Pesce A, West C, Egan City K, Strickland J. Interpretation of urine drug testing in pain patients. <em>Pain Med</em>. 2012;13(7):868-885. PMID: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22494459" class="ext-link">22494459</a><span class="ext"></span></li><li><a name="udt_twelve" id="5_ref_12"></a>Passik SD, Kirsh KL. Managing pain in patients with aberrant drug-taking behaviors. <em>J Support Oncol</em>. 2005;3(1):83-86.</li></ol></div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
              <div id="footer">
                <div class="ft clearfix">
                  <div class="ft-wr clearfix">
                    <span>
                      Any product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
                    </span>
                  </div>

                  <div class="ft-wr clearfix">
                    <div class="pf-logo fl">
                      <img alt="Pfizer Logo" height="35" src="img\pfizer-logo.png" width="56">
                    </div>

                    <p class="fl">
                      Copyright &nbsp; 2014 Pfizer Inc. All rights reserved. EMB695705-01
                    </p>
                  </div>
                </div>
              </div>
          </div>
      </div>
  </body>

</html>
